CELL AND GENE THERAPY

Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx™ Genome Engineering Platform

Amyris | October 06, 2021

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company. Amyris and Inscripta will also explore joint research and development opportunities to expand the Onyx platform functionality.

Amyris' product development and formulation team uses a proprietary Lab-to-Market™ operating system to develop and scale a growing portfolio of sustainable ingredients. The Onyx platform automates benchtop biofoundry activity and will bring greater genetic diversity and value to Amyris' ingredient development pipeline, complementing Amyris' existing Lab-to-Market operating system with the goal of improving efficiency and reducing timelines for the development of future molecules. To date, Amyris has successfully commercialized 13 sustainable ingredients, which are formulated in over 20,000 products and used by over 300 million consumers, demonstrating the growing demand for sustainable products with clean and effective ingredients.

Automated, high-throughput gene editing is revolutionizing the writing of genomes the way next-generation sequencing transformed the reading of genomes. Inscripta is the first company to deliver an integrated and intuitive benchtop platform that will expand access to scalable, robust genome engineering and help scientists develop solutions to some of today's most pressing challenges.

"Amyris has shown the world how new products can be made more sustainable through biology. Their team has high proficiency in utilizing cutting-edge technology, and we are excited they will be pioneering the use of our platform," said Sri Kosaraju, President and CEO of Inscripta. "We have great regard for Amyris' mission, and we are committed to seeing the Onyx platform become a substantial contributor to new clean chemistry products in the future."

"The Onyx platform offers significant potential for generating greater genetic diversity in our projects, which we expect to lead to more efficient product innovation," said Sunil Chandran, Senior Vice President of Research and Development at Amyris. "Inscripta's platform seamlessly integrates with our own and opens up new experimentation avenues for our scientists to continue bringing unique bio-based products to customers. We pride ourselves on continuous innovation and expect Onyx to help us expand our pipeline, while achieving lower costs and reducing time to market."

For more information about Amyris visit amyris.com and to learn about Onyx, visit www.inscripta.com/products.

About Inscripta
Inscripta is a life science technology company enabling scientists to solve some of today's most pressing challenges with the first benchtop system for genome editing. The company's automated Onyx platform, consisting of an instrument, consumables, assays, and software, makes CRISPR-based genome engineering accessible to any research lab. Inscripta supports its customers around the world from facilities in Boulder, Colorado; San Diego and Pleasanton, California; and Copenhagen, Denmark. To learn more, visit Inscripta.com and follow @InscriptaInc.

About Amyris
Amyris (Nasdaq: AMRS) is a science and technology leader in the research, development and production of sustainable ingredients for the Clean Health & Beauty and Flavors & Fragrances markets. Amyris uses an impressive array of exclusive technologies, including state-of-the-art machine learning, robotics and artificial intelligence. Our ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris is proud to own and operate a family of consumer brands - all built around its No Compromise® promise of clean ingredients: Biossanceâ clean beauty skincare, Pipetteâ clean baby skincare, Purecane™, a zero-calorie sweetener naturally derived from sugarcane, Terasanaâ clean skincare treatment, Costa Brazil luxury skincare, OLIKA hygiene and wellness, Rose Inc.™ clean color cosmetics and JVN™ clean haircare.

Spotlight

The infant gut microbiota has a high abundance of antibiotic resistance genes (ARGs) compared to adults, even in the absence of antibiotic exposure. Here we study potential sources of infant gut ARGs by performing metagenomic sequencing of breast milk, as well as infant and maternal gut microbiomes. We find that fecal ARG and mobile genetic element (MGE) profiles of infants are more similar to those of their own mothers than to those of unrelated mothers.

Spotlight

The infant gut microbiota has a high abundance of antibiotic resistance genes (ARGs) compared to adults, even in the absence of antibiotic exposure. Here we study potential sources of infant gut ARGs by performing metagenomic sequencing of breast milk, as well as infant and maternal gut microbiomes. We find that fecal ARG and mobile genetic element (MGE) profiles of infants are more similar to those of their own mothers than to those of unrelated mothers.

Related News

MEDICAL

GT Molecular, Rapidly Expanding Molecular Diagnostics Biotech, Launches Two Highly Sensitive Tests for the Dangerous UK Variant of SARS-CoV-2

GT Molecular | January 13, 2021

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes networks with a quick, exceptionally savvy technique to comprehend the measure of viral transmission inside a local area. Everybody inside a local area gives an example as a flush to the wastewater treatment office and a solitary wastewater test can cover a large number of individuals for a simple portion of what a clinical test for an individual expenses. Moreover, the presence of the infection in wastewater can go before nearby flare-ups locally by as long as seven days, giving wellbeing authorities time to prepare and increase testing. By applying this technique for local area wastewater checking to the recently coursing UK variation, GT Molecular is the first to go above and beyond and really "genotype the sewer".

Read More

AI

Deargen Announces New Model for Optimizing Drug Candidate Molecules With Nearly Doubled Performance Compared to Existing Models

Deargen | April 12, 2021

Deargen, a drug research and development biotech company based on artificial intelligence (AI), announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference, and Learning (ACM CHIL) 2021. CMG technology can modify many properties of molecules at the same time. The Association for Computing Machinery (ACM), based in New York, is one of the world's most prominent academic organizations. The ACM was founded in 1947 and now has over 100,000 members worldwide. The ACM Conference on Health, Inference, and Learning 2021 was held online on April 8th as a healthcare conference. Deargen's latest CMG technology overcomes the limitations of current models for predicting molecule properties. Deargen's test results revealed that the new CMG method enhances efficiency by nearly doubling as compared to existing versions such as MolDQN and VJTNN. Deargen tried to improve aniracetam, which has the lowest binding affinity of dopamine D2-type receptor (DRD2) among 28 DRD2-targeted compounds in clinical or pre-clinical trials, in the most recent report. The study discovered that aniracetam's DRD2 binding affinity was highly enhanced while its other properties remained relatively unchanged. The technology of optimizing properties of candidate molecules in the process of developing new drugs, such as efficacy, toxicity, and structural similarity, is positioning itself as a key strategy for reducing costs and time required for drug development. Models that predict properties of previously proposed molecules, such as MolDQN, VJTNN, and VSeq2Seq, are considered to have limitations when used to produce new drugs because they either alter properties of molecules that must be retained by optimizing only one property or take very long to process data. Deargen's CMG model, on the other hand, will optimize only desired properties while minimizing changes in other properties that are meant to be retained as set by molecule design as it can consider multiple properties at the same time. Since it takes less time to examine, it can be directly applied to the development of new drugs. “Not only is our representative technology, MT-DTI, being used for discovering various new substances, including treatment prediction for COVID-19, but we are also poised to provide more advanced new drug development services by developing an ensemble of CMG models with our other platform MolEQ,” said Bonggeun Shin, Deargen's Chief Artificial Intelligence Officer. Deargen President Kilsoo Kang said, "Deargen has accomplished drug development technologies on a global level and continues to invest in advancing these technologies and extending their support range." “The most recent technological advancement will provide an important momentum in the development of AI-powered new drugs.”

Read More

INDUSTRIAL IMPACT

n-Lorem Foundation Partners with Argonaut to Manufacture ASO Medicines for Patients with Nano-rare Diseases

Argonaut Manufacturing Services | February 02, 2022

Argonaut Manufacturing Services, a leading contract manufacturing organization, and n-Lorem, a nonprofit foundation, today announced a new partnership that supports and reduces the cost of manufacturing of n-Lorem’s experimental antisense oligonucleotide medicines developed for nano-rare disease patients for free, for life. “Providing nano-rare patients, who would otherwise be largely ignored by our current drug discovery paradigm, with a personalized approach for free is a remarkable undertaking and one that requires the commitment of many people and organizations. We are pleased to add Argonaut to our growing list of the industry’s best to support the highest-quality drug discovery, development, and manufacturing for our patients. Reducing the cost of manufacturing translates into lower per-patient costs, which is important for our non-profit and important for our patients who depend upon us and our partners. At n-Lorem, we are fortunate that our partners can integrate seamlessly and efficiently with us and together we work toward making a difference for our nano-rare patient today and tomorrow.” Stanley T. Crooke, M.D., Ph.D., Founder, CEO and Chairman of n-Lorem Foundation “At Argonaut, we are incredibly proud to be working with this distinguished group of experts at the n-Lorem Foundation. We are focused on delivering the best contract manufacturing support to the innovators and creators, in the biopharma industry. Partnering with the n-Lorem Foundation provides us with the unique opportunity to apply our leading aseptic drug product manufacturing technology in support of nano-rare patients,” said Wayne Woodard, Founder and CEO of Argonaut. “I have been impressed with Stan’s vision and leadership with n-Lorem's charitable approach, and the overall progress of the foundation in such a short time. We are committed strategic partners as we understand that there are > 7,000 known rare to nano-rare diseases. Stan and I share a vision that these patient groups will have access to the life improving or lifesaving drugs that need to be developed. As such, we are honored to work with n-Lorem.” “For decades, patient care for rare disease and now nano-rare patients has improved with technological advancement. n-lorem has established the best partners in rare disease research, and we at Argonaut will be the final step in the sterile fill finish of these life-saving therapies. Our world class platform and expertise in drug product manufacturing were designed specifically for small batch drug product manufacturing that is specifically valuable for rare and orphan disease. This expertise and leadership is what we bring together with n-Lorem,” said Eric Blair, Chief Commercial Officer at Argonaut. About Argonaut Manufacturing Services, Inc. Argonaut Manufacturing Services is an FDA registered, FDB approved, ISO 13485:2016 cGMP contract manufacturing organization dedicated to providing custom manufacturing and supply chain solutions for life science, molecular diagnostics, and biopharmaceutical companies. Life sciences and molecular diagnostics services include formulation, filling, lyophilization, and kitting, while biopharmaceutical services feature state-of-the-art automated aseptic fill-finish equipment for sterile injectable drugs. All projects are supported by a senior project management group, full analytical quality control service offering and global shipping logistics. From procurement through distribution, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. About n-Lorem n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility, and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals. Nano-rare patients describe a very small group of patients who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and received over 100 applications for treatment with more than 50 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics.

Read More